Avila gets new US patent
The new patent covers compositions of matter for a particular class of targeted covalent drugs that selectively and irreversibly inhibit kinases such as members of the epidermal growth
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.